Abstract
Background The Diagnostic and Statistical Manual of Mental Disorders (DSM-V) issued new diagnostic criteria for autism spectrum conditions (ASC) which excluded cases of Asperger’s syndrome (AS) and pervasive developmental disorder not otherwise specified (PDD-NOS). This negatively affected the support received by those affected. In this study, we explored if AS can be considered a subtype of autism.
Methods We explored if AS is considered a subtype of autism through gene network analysis. We analysed the GEO microarray data of 170 autism patients, then, used a weighted gene co-expression network (WGCNA) pipeline. We explored whether these modules share the same expression patterns across autism subtypes. The study had 170 patients grouped into three groups: AS, autism, and PDD-NOS.
Results Twenty-one genetic modules were constructed for autism spectrum conditions. However, only AS had a significant downregulation in one of the modules. The module genes were significantly involved in the regulation of proteolysis, catabolic process, and NF-kappaB signalling. Pathway analysis showed the association of these genes with RIPK1-mediated necrosis and regulation of necroptotic cell death. Brain enrichment analysis showed a spatiotemporal distribution. There was significant gene enrichment in the prefrontal cortex during infancy and childhood then it changes in adulthood to be more abundant in the cingulum bundle, and corpus callosum.
Conclusions Our results suggest AS can be a distinct subtype of ASD, showing a similar gene expression pattern. Spatiotemporal distribution of the module genes in different brain regions explains the high functionality in individuals with AS.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We used the microarray data that is publicly available through GEO database (ID: GSE18123
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
E-mails: Adam A. Dmytriw: adam.dmytriw{at}gmail.com, Sadiq Naveed: sadiq.naveed{at}hhchealth.org, Sherief Ghozy: ghozy.sherief{at}mayo.edu, Sara Morsy: Skhalil7{at}bradford.ac.uk
We have no known conflict of interest to disclose.
Data Availability
All data produced are available online at GEO database (ID: GSE18123).
